Try our Advanced Search for more refined results
Life Sciences
-
March 19, 2026
Legislative Update: Cannabis And Psychedelics Bill Roundup
Virginia lawmakers last week gave final approval to legislation that would tax and regulate the sale of adult-use cannabis, Georgia legislators passed a dramatic expansion of the state's medical cannabis program, and Iowa lawmakers approved a bill to designate kratom as a Schedule I substance. Here are the major moves in cannabis and psychedelics legislation from the past week.
-
March 19, 2026
Drug Co. Can't Claim Most Docs Contain Trade Secrets At Trial
A Manhattan federal judge ruled Thursday that a pharmaceutical consulting company won't be allowed to argue to a jury that thousands of documents it did not enter into evidence contain trade secrets amid an ongoing misappropriation trial.
-
March 19, 2026
Still No Shenanigans: Fed. Circ. Keeps Review Bar High
The Federal Circuit's rejection of all mandamus petitions asking it to rein in the way U.S. Patent and Trademark Office leadership is evaluating patent challenges cements the appeals court's near-impossible standard for reviewing institution decisions, attorneys say.
-
March 19, 2026
Calif. Families Sue Rady Health Over Move To End Trans Care
Four families have asked a state judge to prevent California's largest pediatric health system from cutting off gender-affirming care for minors, alleging the move would violate state anti-discrimination laws and leave them scrambling to find new providers, some more than 100 miles away.
-
March 19, 2026
Goodwin, S&C Steer Up-To $785M Sale Of ADHD Drug
Goodwin Procter LLP-advised Collegium Pharmaceutical Inc. unveiled plans Thursday to acquire attention deficit hyperactivity disorder drug Azstarys from Sullivan & Cromwell LLP-led Corium Therapeutics Holdings LLC for up to $785 million.
-
March 19, 2026
CVS, Caremark Pocket Money Meant For Rebates, Suit Claims
CVS charges drug manufacturers "exorbitant" fees in exchange for pushing their products, then pockets the money instead of funneling it toward customer rebates as it promises, a federal lawsuit alleges, accusing the company of collecting billions of dollars at customers' expense and violating the anti-racketeering statute.
-
March 19, 2026
Zynex Gets OK For Ch. 11 Plan Reducing Debt By $50M
Zynex Inc., a pain management medical device maker, received confirmation Thursday of its Chapter 11 plan, which reduces its debt by about $50 million and turns over the company to its creditors.
-
March 18, 2026
Key Details As 3rd Circ. Ponders FCA's Fate, $1.6B J&J Fine
Third Circuit judges Wednesday explored divergent views of the False Claims Act's constitutionality and a record fraud verdict against Johnson & Johnson, expressing little eagerness to gut the FCA's whistleblower mechanism, and voicing uncertainty about evidence and jury instructions underpinning the drug promotion punishment.
-
March 18, 2026
Apple Took Masimo IP But No Remedy Warranted, Judge Says
A California federal judge determined Apple misappropriated two out of five of Masimo Corp.'s asserted trade secrets related to pulse oximetry technology for its smartwatches, but found Masimo's requests for an injunction and attorney fees unwarranted, according to a December bench trial ruling that was unsealed this week.
-
March 18, 2026
Stryker Hit With Another Suit After Cyberattack
Another proposed class action has been filed against Michigan-based medical technology company Stryker Corp. in the wake of a March 11 cyberattack on the company that was reportedly perpetrated by hackers tied to Iran.
-
March 18, 2026
FINRA Says Compliance Chief Took Part In Pre-IPO Fraud
The Financial Industry Regulatory Authority has alleged in a disciplinary proceeding that Spartan Capital Securities LLC, its CEO and chief compliance officer defrauded customers by liquidating their own pre-initial public offering shares of a pharmaceutical company more quickly and at a higher price than their customers.
-
March 18, 2026
Squires' Latest Order Grants 9 Patent Reviews, Spurns 6
A new bulk order from the U.S. Patent and Trademark Office director on America Invents Act patent challenges denied six petitions and granted nine others, bringing the total number of institution decisions he's made since October past 400.
-
March 18, 2026
Abbott Investors Ink $40M Deal Over Infant Formula Crisis
Shareholders who brought a derivative suit over Abbott Laboratories' management of the 2022 infant formula crisis asked an Illinois judge on Tuesday to approve a settlement that includes $40 million in investments in food safety and corporate reforms, and $15.85 million in attorney fees.
-
March 18, 2026
USPTO Wants 900 New Patent Examiners By October
The U.S. Patent and Trademark Office plans to hire 900 patent examiners focusing on sciences and engineering by Oct. 1, two agency managers said in a Wednesday webinar.
-
March 18, 2026
NC Judge Moves Ex-Exec's Wage Fight With Cancer Co. To Va.
A North Carolina federal judge agreed to transfer a former C-suite executive's unpaid wages case against a Canadian cancer testing and treatment company to Virginia, where its U.S. headquarters are, finding the Old Dominion is the better venue.
-
March 18, 2026
Food Cos. Get Another Shot At David Protein Antitrust Case
A New York federal court is letting low-calorie food producers take another shot at their antitrust claims accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after purchasing the ingredient's only supplier.
-
March 18, 2026
DLA Piper Lands Shook Hardy Products Liability Pro In Miami
A longtime Shook Hardy & Bacon LLP trial lawyer specializing in high-stakes product liability and complex litigation has joined DLA Piper in Miami, the firm announced Wednesday.
-
March 18, 2026
Axion Cleared Of False Advertising Before Agilent Patent Trial
Ahead of a patent infringement trial set to begin next week, a Delaware federal judge has addressed false advertising claims against biotechnology firm Axion and ruled there was no genuine dispute that a set of Axion advertisements deceived customers.
-
March 18, 2026
Biotech Investor Blames Pierce Atwood For Messy Asset Sale
A Ukrainian billionaire who was recently ordered to pay other investors in a failed genetic testing company more than $1.8 million in damages is blaming the Pierce Atwood LLP lawyers who advised him on what a court later found to be a "fundamentally unfair" forced asset sale.
-
March 18, 2026
Latham Hires Desmarais IP Partner In DC
Latham & Wakins LLP has hired a Desmarais LLP partner in D.C., who helped represent GlaxoSmithKline Biologicals in an ongoing infringement suit against Moderna Inc., the firm announced Tuesday.
-
March 17, 2026
Pot Co. Escapes Potency Suit, Judge Warns Plaintiff Firm
MariMed and other cannabis companies beat claims they intentionally mislabeled their products to sidestep Illinois THC potency limits, with a federal judge highlighting the string of consumer-led suit losses and warning counsel to "heed the strong and universal concerns about the plausibility of their legal theories."
-
March 17, 2026
NeoGenomics Beats Investor Suit Over Growth Driver Claims
Cancer diagnostics company NeoGenomics Inc. no longer faces a proposed investor class action alleging it mischaracterized its growth drivers, including by failing to disclose that a rainmaking unit potentially ran afoul of anti-kickback laws, after a Manhattan federal judge held the suit failed to show the company had intentionally misled the markets.
-
March 17, 2026
9th Circ. Backs Rare FCA Theory In Huge Drug Prices Program
In a novel and potentially far-reaching decision, the Ninth Circuit on Tuesday revived a major hospital chain's False Claims Act suit accusing large pharmaceutical companies of massive overcharges in a prominent drug discount program where pricing disputes are common.
-
March 17, 2026
Bard And AngioDynamics Resolve 11-Year Patent Dispute
A Delaware federal judge on Tuesday closed the book on a vascular port patent dispute between C.R. Bard and AngioDynamics that had been pending for over 11 years, citing a settlement after the Federal Circuit invalidated Bard patents that a jury said AngioDynamics infringed.
-
March 17, 2026
Dr. Oz Claims Florida Also Has Healthcare Fraud Problem
Dr. Mehmet Oz, the administrator for the Centers for Medicare & Medicaid Services, announced Tuesday that he is taking his efforts to combat healthcare-related fraud to Florida, where he says millions of dollars have been wasted on schemes involving durable medical equipment.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
Series
Coaching Soccer Makes Me A Better Lawyer
Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.
-
Series
Law School's Missed Lessons: The Human Element
Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.
-
Avoid The Unexpected When Drafting License Agreements
The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.
-
CMS Healthcare Enforcement Initiatives May Cause Disruption
The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.
-
The Benefits Of Choosing A Niche Practice In The AI Age
As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.
-
How PBMs Can Adapt To Plan Sponsors' Disclosure Demands
As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.
-
What New Animal Welfare Enforcement Push Means For Cos.
The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.
-
How To Engage With Gov't's Direct-To-Consumer Drug Policy
The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.
-
Series
Podcasting Makes Me A Better Lawyer
Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.
-
Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts
Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.
-
Tax Court Ruling Signals Cross-Border Loan Scrutiny
The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.
-
Lessons From Justices' Split On Major Questions Doctrine
The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.
-
Drug Wholesaler's DPA Shows Imperfect Efforts Still Count
Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.
-
Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot
The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.
-
When MDLs Drag, State Courts Can Speed Mass Tort Results
Understanding the structural dynamics that can delay resolution in multidistrict litigation is essential to understanding why a state court strategy is sometimes not merely attractive, but necessary for plaintiffs seeking timely and just outcomes, say attorneys at DiCello Levitt.